BioSpace News Archive

Drug Development

UNITY Shares Nearly Halved after Lead Asset Fails to Match Regeneron’s Eylea

UNITY Biotechnology’s lead asset, UBX1325, failed to show non-inferiority to Regeneron’s blockbuster Eylea in a Phase II wet age-related macular degeneration trial.

March 27, 2023
·
1 min read
·
Ana Mulero
Drug Development

BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn

The FDA has granted an advisory committee meeting for BrainStorm Cell Therapeutics’ investigational ALS therapy, NurOwn, the company announced Monday.

March 27, 2023
·
6 min read
·
Heather McKenzie
Drug Development

Novartis’ Kisqali Cuts Recurrence Risk in Early-Stage Breast Cancer

Topline data from the Phase III NATALEE study showed Novartis’ Kisqali met its primary endpoint, reducing the risk of recurrence in early breast cancer.

March 27, 2023
·
2 min read
·
Tristan Manalac
Career Advice

5 High-Paying Life Science Jobs that Don’t Include Management

If management isn’t your strength, there are several upper-level positions that don’t require you to manage others. Here are five high-paying life science jobs that don’t include management.

March 27, 2023
·
2 min read
·
Rosemary Scott
Drug Development

Pharming’s Leniolisib Gains FDA Approval in Ultra-Rare Disease

The FDA approved Pharming’s leniolisib, now to be marketed as Joenja, for the treatment of the ultra-rare disease-activated phosphoinositide 3-kinase delta syndrome, the company announced Friday.

March 27, 2023
·
2 min read
·
Tristan Manalac
Drug Development

ArriVent Snags $155M for NSCLC Treatment in Record Low Series B Period

Despite a tough financing market, ArriVent Biopharma closed a $155 million Series B to fund a pivotal Phase III trial of its non-small cell lung cancer asset.

March 27, 2023
·
2 min read
·
Kate Goodwin
Business

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’) today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023.

March 27, 2023
·
2 min read
Business

Danaher Schedules First Quarter 2023 Earnings Conference Call

Danaher Corporation announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

March 27, 2023
·
1 min read
BioMidwest

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering

INVO Bioscience, Inc. announced the closing of its previously announced registered direct offering of 3,680,000 shares of common stock, priced at-the-market under Nasdaq rules.

March 27, 2023
·
4 min read
Drug Development

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 NRG‑GY018 trial investigating KEYTRUDA.

March 27, 2023
·
68 min read